Appendix Table 1Pertinent systematic reviews

ReferenceInclusion CriteriaTotal Studies IncludedTotal Pts IncludedAMSTAR rating
Al-Mallah 200692All randomized, placebo controlled trials of ACEIs use in patients with CAD and preserved LV function (LVEF≥40%)633,5007/11
Dagenais 200693HOPE, EUROPA and PEACE (the three main large trials of ACEIs in patients with atherosclerosis, but without heart failure or LSVD)329,8052/11
Danchin 200694All placebo-controlled randomized trials with a follow-up of 2 years or longer performed in patients who had stable CAD and either no signs or symptoms of heart failure or no documented LV dysfunction (no LVEF<35%)733,9609/11
Saha 200795All randomized, placebo controlled clinical trials with mean study duration of at least 12 months, a use of a tissue-selective ACEI (ramipril, perindopril, quinapril, or trandolapril), and strict inclusion of patients with cardiovascular disease who either had documented EKG evidence of normal left ventricular function (LVEF>40%) or had no clinical symptoms of CHF at the time of randomization431,5557/11
Lang 200896All randomized, placebo controlled clinical trials with mean study duration of at least 12 months, a use of a tissue-selective ACEI (ramipril, perindopril, quinapril, or trandolapril), patients with documented DM with evidence of normal left ventricular systolic function or who had no symptoms of congestive heart failure at the onset of the study, and risk factors in addition to DM, according to the Framingham classification410,3286/11
Saha 200897All RCTs with mean follow-up period of at least 12 months, and that compared effects of tissue-selective ACEI (ramipril, perindopril, quinapril, or trandolapril), with placebo, in patients with known DM who either had documented evidence of normal left ventricular systolic function or had no clinical symptoms of congestive heart failure at the start of the study410,3286/11

From: Appendix C, Additional Evidence Tables and Analyses

Cover of Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease
Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease [Internet].
Comparative Effectiveness Reviews, No. 18.
Coleman CI, Baker WL, Kluger J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.